Cited by 255COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchInflammation biomarkers and pathways

Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients

Open access
German COVID-19 Omics Initiative (DeCOI), Aschenbrenner, Anna C., Mouktaroudi, Maria, Krämer, Benjamin, Oestreich, Marie, Antonakos, Nikolaos, Nuesch-Germano, Melanie, Gkizeli, Konstantina +48 more·2021·Genome Medicine

Published version of a preprint

Abstract

Background: The SARS-CoV-2 pandemic is currently leading to increasing numbers of COVID-19 patients all over the world. Clinical presentations range from asymptomatic, mild respiratory tract infection, to severe cases with acute respiratory distress syndrome, respiratory failure, and death. Reports on a dysregulated immune system in the severe cases call for a better characterization and understanding of the changes in the immune system. Methods: In order to dissect COVID-19-driven immune host responses, we performed RNA-seq of whole blood cell transcriptomes and granulocyte preparations from mild and severe COVID-19 patients and analyzed the data using a combination of conventional and data-driven co-expression analysis. Additionally, publicly available data was used to show the distinction from COVID-19 to other diseases. Reverse drug target prediction was used to identify known or novel drug candidates based on finding from data-driven findings. Results: Here, we profiled whole blood transcriptomes of 39 COVID-19 patients and 10 control donors enabling a data-driven stratification based on molecular phenotype. Neutrophil activation-associated signatures were prominently enriched in severe patient groups, which was corroborated in whole blood transcriptomes from an independent second cohort of 30 as well as in granulocyte samples from a third cohort of 16 COVID-19 patients (44 samples). Comparison of COVID-19 blood transcriptomes with those of a collection of over 3100 samples derived from 12 different viral infections, inflammatory diseases, and independent control samples revealed highly specific transcriptome signatures for COVID-19. Further, stratified transcriptomes predicted patient subgroup-specific drug candidates targeting the dysregulated systemic immune response of the host. Conclusions: Our study provides novel insights in the distinct molecular subgroups or phenotypes that are not simply explained by clinical parameters. We show that whole blood transcriptomes are extremely informative for COVID-19 since they capture granulocytes which are major drivers of disease severity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-020-00823-5

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A reverse transcriptomics analysis of patient blood immune cells flagged dexamethasone and other corticosteroids as possibly helpful for some severe cases.

    “Reverse transcriptomics of blood immune cells derived from COVID-19 patients predicted the broadly anti-inflammatory drug dexamethasone and other corticosteroids as potentially beneficial for a subgroup of severely ill COVID-19 patients (Aschenbrenner et al., 2021).”

    From COVID-19 and the human innate immune system (2021) · cites this paper as Aschenbrenner et al., 2021

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [101]Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. PMC7583697 33053279

Cited by

Sorted by citations

Authors
(DeCOI), G. C.-1. O. I., Aschenbrenner, A. C., Mouktaroudi, M., Krämer, B., Oestreich, M., Antonakos, N., Nuesch-Germano, M., Gkizeli, K., Bonaguro, L., Reusch, N., Baßler, K., Saridaki, M., Knoll, R., Pecht, T., Kapellos, T. S., Doulou, S., Kröger, C., Herbert, M., Holsten, L., Horne, A., Gemünd, I. D., Rovina, N., Agrawal, S., Dahm, K., van Uelft, M., Drews, A., Lenkeit, L., Bruse, N., Gerretsen, J., Gierlich, J., Becker, M., Händler, K., Kraut, M., Theis, H., Mengiste, S., De Domenico, E., Schulte-Schrepping, J., Seep, L., Raabe, J., Hoffmeister, C., ToVinh, M., Keitel, V., Rieke, G., Talevi, V., Skowasch, D., Aziz, N. A., Pickkers, P., van de Veerdonk, F. L., Netea, M. G., Schultze, J. L., Kox, M., Breteler, M. M. B., Nattermann, J., Koutsoukou, A., Giamarellos-Bourboulis, E. J., & Ulas, T.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • University of Bonn (DE)
  • National and Kapodistrian University of Athens (GR)
  • Radboud University Nijmegen (NL)
  • University Hospital Bonn (DE)
Corresponding author
Ulas, Thomas
Venue
Genome Medicine
Published
2021-01-13
Volume
13
Issue
1
Pages
7-7
ISSN
1756-994X (ISSN-L)
OpenAlex
W3120994437
Cited by
255
References
137
Citations by year
2026: 11 · 2025: 19 · 2024: 32 · 2023: 50 · 2022: 80 · 2021: 57 · 2020: 6
FWCI
17.50
Type
journal article
Language
en
Open access
Locations
  • Genome Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Funders
  • Deutsches Zentrum für Infektionsforschung
  • Francis Crick Institute (10134)
  • Deutsche Forschungsgemeinschaft (SFBTR57, SPP193 7, SFB 704, EXC 2151, GRK 2168, SCHU 950/8-1, 390873048)
  • Bundesministerium für Bildung und Forschung (01EA1809C, EXC2151, SPP1937, 01EA1410C, 390873048)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (833247)
  • National and Kapodistrian University of Athens
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
COVID-19 pandemic, SARS-CoV-2, disease severity, neutrophil activation, whole blood transcriptome, granulocytes, immune response, gene expression signatures, patient stratification, drug target prediction, drug candidates, viral infection, inflammatory diseases
MeSH terms
COVID-19, COVID-19 Drug Treatment, Antiviral Agents, Humans, Neutrophils, Phenotype, RNA, Severity of Illness Index, Down-Regulation, Up-Regulation, Case-Control Studies, Sequence Analysis, RNA, Principal Component Analysis, Drug Repositioning, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review